What’s the difference between a ‘pre-approval’ medicine and an ‘unapproved’ or ‘elsewhere approved’ medicine’?
Remember the hypospray from Star Trek? Maybe it's close to reality
The potential of neuroprotective agents for a whole new form of treatment
A groundbreaking year helping patients access the latest approved medicines
Darzalex (daratumumab) combination under review as first-line option
Is there substance to the claims that it's a groundbreaking treatment?
We talk to Sera, our Medicines Sourcing Manager about why drug delays happen
Why can it take us three to four weeks to deliver a medicine, and what can customers do to speed things up?
How effective is alectinib (Alecensa)? The latest news and updates.
Our review of the SOCAP social impact event in San Francisco
An insight into the team, and how we constantly review our progress at TheSocialMedwork
An easy-to-understand infographic displaying the results from the clinical trial
Online counsellor Nicole Hind shares how to help our brains and bodies deal with a diagnosis
A chat with our very first angel investor about patients, doctors and injecting innovation into the healthcare sector
Gaining a deeper understanding of Ocrevus (ocrelizumab) for the treatment of MS through clinical trials
For US patients and patients worldwide
Amsterdam leads European cities as top tech destination and why it’s only natural that it is home to TheSocialMedwork.
Missed our blog on the latest MS news and treatments? Here's a quick summary in our latest infographic.
As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.
With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.
Online shopping giants Amazon turn their eye to the online pharmacy market.
Get the latest news on MS research, the FDA approval of Ocrevus (ocrelizumab) for both relapsing and progressive forms of MS, insights and resources.
PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.
What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?
The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment.
Mirjam Bink’s story about her father and his attempt to access a new treatment for multiple system atrophy.
TheSocialMedwork organised the perfect spring day to reflect and grow our 2017 startup strategy.